As competitive as the obesity drug market has become, Novo Nordisk's decision to slash the prices of its GLP-1 agonist drugs ...
Danish pharma major Novo Nordisk has slashed the price of Wegovy by up to 37%, to take on its key rival Eli Lilly. Here's how ...
Eli Lilly's tirzepatide acts on two hormonal pathways, so it's called a dual GIP/GLP-1 receptor agonist, and it entered the market as Mounjaro for Type 2 diabetes and as Zepbound for weight management ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback